Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.64 |
| ▸ | MMP2 | P08253 | 3/20 | 0.61 |
| ▸ | MMP9 | P14780 | 3/20 | 0.61 |
| ▸ | ACE | P12821 | 1/20 | 0.60 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
| ▸ | MMP7 | P09237 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CPB1 | P15086 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10772400 | 0.84 | FOLH1 (0.68) | FOLH1MMP2MMP9ACEMMP1 | |
| SCHEMBL15249558 | 0.84 | FOLH1 (0.71) | FOLH1MMP2MMP9MMP1MMP3 | |
| SCHEMBL4561005 | 0.84 | FOLH1 (0.78) | FOLH1MMP2MMP9CPB1CPB2 | |
| SCHEMBL464715 | 0.84 | FOLH1 (0.78) | FOLH1MMP2MMP9CPB1CPB2 | |
| SCHEMBL806151 | 0.84 | FOLH1 (0.78) | FOLH1MMP2MMP9CPB1CPB2 | |
| SCHEMBL25406900 | 0.84 | FOLH1 (0.71) | FOLH1MMP2MMP9MMP1MMP3 | |
| SCHEMBL31265517 | 0.83 | FOLH1 (0.69) | FOLH1MMP2MMP9MMP1MMP3 | |
| SCHEMBL13227705 | 0.83 | FOLH1 (0.69) | FOLH1MMP2MMP9MMP1MMP3 | |
| SCHEMBL31265519 | 0.83 | FOLH1 (0.69) | FOLH1MMP2MMP9MMP1MMP3 | |
| SCHEMBL7323375 | 0.82 | FOLH1 (0.66) | FOLH1MMP2MMP9ACEMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550860-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150165055-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | CERULEAN PHARMA INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20140288023-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8680202-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20140044669-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8580244-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580243-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580242-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8518388-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130203700-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20120301424-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8314230-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120289480-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120283214-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252276-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120178711-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120065368-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8110179-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7270808-B2 | Having covalently coupled bioactive agent and targeting ligand; controlled release; stability, solubility; reduced toxicity | INSERT THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203700-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, DSC1, SI | FOLH1 1091/4885MMP2 2876/4885MMP9 3322/4885 |
| US-20120289480-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, DSC1, SI | FOLH1 1091/4885MMP2 2876/4885MMP9 3322/4885 |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | DDOST, DSC1, SI | FOLH1 1091/4885MMP2 2876/4885MMP9 3322/4885 |
| US-20120178711-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, DSC1, SI | FOLH1 1091/4885MMP2 2876/4885MMP9 3322/4885 |
| US-20120065368-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, DSC1, SI | FOLH1 1091/4885MMP2 2876/4885MMP9 3322/4885 |
| US-20120283214-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, DSC1, SI | FOLH1 1091/4885MMP2 2876/4885MMP9 3322/4885 |
| US-20140044669-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, DSC1, SI | FOLH1 1091/4885MMP2 2876/4885MMP9 3322/4885 |
| US-20120301424-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, DSC1, SI | FOLH1 1091/4885MMP2 2876/4885MMP9 3322/4885 |
| US-20140288023-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, DSC1, SI | FOLH1 1091/4885MMP2 2876/4885MMP9 3322/4885 |
| US-20150165055-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | SDCBP, DDOST, CD47 | FOLH1 1221/4885MMP2 3603/4885MMP9 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.